BRTX Stock Overview
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioRestorative Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.45 |
| 52 Week High | US$3.67 |
| 52 Week Low | US$1.03 |
| Beta | 62.82 |
| 11 Month Change | -10.53% |
| 3 Month Change | -15.01% |
| 1 Year Change | -22.31% |
| 33 Year Change | -75.24% |
| 5 Year Change | -99.18% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| BRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | -6.5% | -1.0% |
| 1Y | -22.3% | 14.6% | 30.3% |
Return vs Industry: BRTX underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: BRTX underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BRTX volatility | |
|---|---|
| BRTX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BRTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BRTX's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Lance Alstodt | www.biorestorative.com |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
BioRestorative Therapies, Inc. Fundamentals Summary
| BRTX fundamental statistics | |
|---|---|
| Market cap | US$9.69m |
| Earnings (TTM) | -US$1.95m |
| Revenue (TTM) | US$377.00k |
26.5x
P/S Ratio-5.1x
P/E RatioIs BRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRTX income statement (TTM) | |
|---|---|
| Revenue | US$377.00k |
| Cost of Revenue | US$24.73k |
| Gross Profit | US$352.27k |
| Other Expenses | US$2.31m |
| Earnings | -US$1.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 93.44% |
| Net Profit Margin | -518.16% |
| Debt/Equity Ratio | 0% |
How did BRTX perform over the long term?
See historical performance and comparison